Financial Data and Key Metrics Changes - Revenue for the first quarter increased to $48.6 million, representing a 17.4% growth compared to the same period last year, driven by a 14% increase in unit volume and a 3% increase in price [22][24] - Gross profit for the quarter was $34.9 million, with a gross margin of approximately 71.9%, down from 78.8% year-over-year [22][23] - The company reported a net loss of $3.8 million or $0.08 per share, compared to a net loss of $6.6 million or $0.15 per share in the first quarter of the previous year [25] Business Line Data and Key Metrics Changes - The extremities market experienced double-digit growth, with continued adoption of the nerve protection portfolio [12] - In the breast segment, there was a 16% increase in the number of surgeons performing breast resensation procedures, totaling 254 surgeons [15] - The oral, maxillofacial, and head and neck markets showed strong growth from the adoption of the nerve algorithm in mandible reconstruction procedures [15] Market Data and Key Metrics Changes - The company is targeting to generate approximately 66% of its growth in 2025 from high potential accounts, with an average account productivity increase of 24% in the first quarter [10][11] - There were 566 active high potential accounts at the end of the first quarter, representing a 5% increase compared to the same period last year [11] Company Strategy and Development Direction - The company is focused on making nerve care a standard of care for all patients, leveraging clinical evidence and societal support [8][19] - Plans to expand commercial infrastructure include adding sales representatives and conducting professional education programs [12][13] - The biologics license application (BLA) for the advanced nerve graft is on track, with expectations for approval in September [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth strategy, highlighting broad-based growth across the portfolio and the importance of high potential accounts [8][9] - The company anticipates improvements in gross margin following BLA approval and the implementation of process improvements [23][26] Other Important Information - A leadership transition was announced, with Nir Naor stepping down as CFO and Lindsay Hartley appointed as the new CFO [5][6] - The company is maintaining its full-year 2025 revenue growth guidance in the range of 15% to 17% [26] Q&A Session Summary Question: Insights on Avance and BLA approval process - Management does not expect major changes to ordering or shipment for Avance post-approval, and reimbursement pathways will remain unchanged [34] Question: Gross margin concerns - The one-time inventory write-offs were significant, and management expects gross margin to improve throughout the year, particularly after BLA approval [36][37] Question: Sales team expansion - The company plans to have approximately 20 net new sales representatives by the end of the year, with hiring running slightly behind schedule [46] Question: High potential accounts initiative - There are approximately 780 high potential accounts, with 566 active accounts, and management sees opportunities to expand within existing and new accounts [52][53] Question: Clinical studies and evidence generation - Management is committed to generating level one evidence to support clinical adoption and reimbursement, with plans for additional studies [62] Question: BLA process and major checkpoints - The next major milestone is the late cycle meeting with the FDA, and management is confident in the progress made so far [98]